Back to Journals » Drug Design, Development and Therapy » Volume 15

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

Total article views   HTML views PDF downloads Totals
7,337 Dovepress* 6,139+ 496 6,635
PubMed Central* 1,198 210 1,408
Totals 7,337 706 8,043
*Since 14 July 2021
Total mentioned Facebook Delicious Reddit Twitter Others
6 0 0 0 3 3

View citations on PubMed Central and Google Scholar